全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Small Cell Prostate Cancer; Center Review of Two Cases and Testimony of a Rare and Aggressive Disease

DOI: 10.4236/crcm.2024.139049, PP. 410-417

Keywords: Small Cell, Prostate, Cancer, Mortality, Chemoradiation

Full-Text   Cite this paper   Add to My Lib

Abstract:

Small cell cancers were initially described in the lungs and later found to occur in a wide range of organs of the body, constituted a disease entity that is characterized by an aggrieve path/course and a huge disease related mortality. They are also called neuroendocrine tumors with peculiar histologic and biologic disease entity. Here we present two cases of small cell cancer of the prostate seen and managed in our facility with focus on their presentation, disease progression and outcome. The first patient was a 72-year-old retired military officer who presented with a progressively painful scrotal swelling of 3-month duration, and scrotal ulceration with contact bleeding of a month duration associated with a foul-smelling discharge. There was also history of progressive weight lost, loss of appetite and constipation. Patient was pale and lethargic on examination with a foul smelling exophytic scrotal mass. Serum PSA was 4 ng/l (within normal limit). Wedge biopsy and trucut prostate biopsy revealed small cell cancer of the prostate. Patient was resuscitated and prepared for chemoradiation, had a single dose of chemotherapy and died before the second dose. Second patient was a 63-year-old farmer who presented with lower urinary tract symptoms, progressive weight loss and constipation of two months duration, a known hypertensive and diabetic who has been regular on his medication. He was lethargic on examination, pale and unable to stand without support. Trucut prostate biopsy shows small cell cancer of the prostate. He was also resuscitated and being prepared for chemoradiation but died before commencement of treatment.

References

[1]  Wenk, R.E., Bhagavan, B.S., Levy, R., Miller, D. and Weisburger, W. (1977) Ectopic ACTH, Prostatic Oat Cell Carcinoma, and Marked Hypernatremia. Cancer, 40, 773-778.
https://doi.org/10.1002/1097-0142(197708)40:2<773::aid-cncr2820400226>3.0.co;2-i
[2]  Amato, R.J., Logothetis, C.J., Hallinan, R., Ro, J.Y., Sella, A. and Dexeus, F.H. (1992) Chemotherapy for Small Cell Carcinoma of Prostatic Origin. Journal of Urology, 147, 935-937.
https://doi.org/10.1016/s0022-5347(17)37427-x
[3]  Abbas, F., Civantos, F., Benedetto, P. and Soloway, M.S. (1995) Small Cell Carcinoma of the Bladder and Prostate. Urology, 46, 617-630.
https://doi.org/10.1016/s0090-4295(99)80290-8
[4]  Di Sant’Agnese, P.A. (1992) Neuroendocrine Differentiation in Carcinoma of the Prostate. Diagnostic, Prognostic, and Therapeutic Implications. Cancer, 70, 254-268.
https://doi.org/10.1002/1097-0142(19920701)70:1+<254::aid-cncr2820701312>3.0.co;2-e
[5]  Mackey, J.R., Au, H., Hugh, J. and Venner, P. (1998) Genitourinary Small Cell Carcinoma: Determination of Clinical and Therapeutic Factors Associated with Survival. Journal of Urology, 159, 1624-1629.
https://doi.org/10.1097/00005392-199805000-00058
[6]  Spiess, P.E., Pettaway, C.A., Vakar‐Lopez, F., Kassouf, W., Wang, X., Busby, J.E., et al. (2007) Treatment Outcomes of Small Cell Carcinoma of the Prostate. Cancer, 110, 1729-1737.
https://doi.org/10.1002/cncr.22971
[7]  Petraki, C., Vaslamatzis, M., Petraki, K., Revelos, K., Alevizopoulos, N., Papanastasiou, P., et al. (2005) Prostate Cancer with Small-Cell Morphology: An Immunophenotypic Subdivision. Scandinavian Journal of Urology and Nephrology, 39, 455-463.
https://doi.org/10.1080/00365590500199855
[8]  Rekhtman, N. (2010) Neuroendocrine Tumors of the Lung: An Update. Archives of Pathology & Laboratory Medicine, 134, 1628-1638.
https://doi.org/10.5858/2009-0583-rar.1
[9]  Alberti, C. (2010) Neuroendocrine Differentiation in Prostate Carcinoma: Focusing on Its Pathophysiologic Mechanisms and Pathological Features. IL Giornale di Chirurgia, 31, 568-574.
[10]  Global Burden of Disease Cancer Collaboration (2013) The Global Burden of Cancer in 2013. JAMA Oncology, 1, 505-527.
https://doi.org/10.1001/jamaoncol.2015.0735
[11]  Komura, K., Sweeney, C.J., Inamoto, T., Ibuki, N., Azuma, H. and Kantoff, P.W. (2017) Current Treatment Strategies for Advanced Prostate Cancer. International Journal of Urology, 25, 220-231.
https://doi.org/10.1111/iju.13512
[12]  Wang, W. and Epstein, J.I. (2008) Small Cell Carcinoma of the Prostate: A Morphologic and Immunohistochemical Study of 95 Cases. American Journal of Surgical Pathology, 32, 65-71.
https://doi.org/10.1097/pas.0b013e318058a96b
[13]  Nadal, R., Schweizer, M., Kryvenko, O.N., Epstein, J.I. and Eisenberger, M.A. (2014) Small Cell Carcinoma of the Prostate. Nature Reviews Urology, 11, 213-219.
https://doi.org/10.1038/nrurol.2014.21
[14]  Sella, A., Konichezky, M., Flex, D., Sulkes, A. and Baniel, J. (2000) Low PSA Metastatic Androgen—Independent Prostate Cancer. European Urology, 38, 250-254.
https://doi.org/10.1159/000020289
[15]  Umar, S.A., Umar, S.A. and MacLennan, G.T. (2009) Small Cell Carcinoma of the Prostate. Journal of Urology, 181, 838-839.
https://doi.org/10.1016/j.juro.2008.11.006
[16]  Palmgren, J.S., Karavadia, S.S. and Wakefield, M.R. (2007) Unusual and Underappreciated: Small Cell Carcinoma of the Prostate. Seminars in Oncology, 34, 22-29.
https://doi.org/10.1053/j.seminoncol.2006.10.026
[17]  Cecen, K., Karadag, M.A., Demir, A. and Kocaaslan, R. (2014) Small Cell Carcinoma of the Prostate Presenting with Skin Metastasis: A Case Report. Journal of Medical Case Reports, 8, Article No. 146.
https://doi.org/10.1186/1752-1947-8-146
[18]  Bhandari, R., Vengaloor Thomas, T., Giri, S., Kumar, P.P. and Cook-Glenn, C. (2020) Small Cell Carcinoma of the Prostate: A Case Report and Review of the Literature. Cureus, 12, e7074.
https://doi.org/10.7759/cureus.7074
[19]  Kawai, S., Hiroshima, K., Tsukamoto, Y., Tobe, T., Suzuki, H., Ito, H., et al. (2003) Small Cell Carcinoma of the Prostate Expressing Prostate-Specific Antigen and Showing Syndrome of Inappropriate Secretion of Antidiuretic Hormone: An Autopsy Case Report. Pathology International, 53, 892-896.
https://doi.org/10.1046/j.1440-1827.2003.01568.x
[20]  Stein, M.E., Kuten, A., Bernstein, Z., Abacioglu, U., Sengoz, M., Miller, R.C., et al. (2008) Small Cell (Neuroendocrine) Carcinoma of the Prostate: Etiology, Diagnosis, Prognosis, and Therapeutic Implications—A Retrospective Study of 30 Patients from the Rare Cancer Network. The American Journal of the Medical Sciences, 336, 478-488.
https://doi.org/10.1097/maj.0b013e3181731e58
[21]  Tětu, B., Ro, J.Y., Ayala, A.G., Johnson, D.E., Logothetis, C.J. and Ordonez, N.G. (1987) Small Cell Carcinoma of the Prostate Part I a Clinicopathologic Study of 20 Cases. Cancer, 59, 1803-1809.
https://doi.org/10.1002/1097-0142(19870515)59:10<1803::aid-cncr2820591019>3.0.co;2-x
[22]  Trotz, C. (2003) Prostate Cancer with a Normal PSA: Small Cell Carcinoma of the Prostate—A Rare Entity. The Journal of the American Board of Family Medicine, 16, 343-344.
https://doi.org/10.3122/jabfm.16.4.343
[23]  Yashi, M., Terauchi, F., Nukui, A., Ochi, M., Yuzawa, M., Hara, Y., et al. (2006) Small-Cell Neuroendocrine Carcinoma as a Variant Form of Prostate Cancer Recurrence: A Case Report and Short Literature Review. Urologic Oncology: Seminars and Original Investigations, 24, 313-317.
https://doi.org/10.1016/j.urolonc.2005.08.022
[24]  Okada, H., Gotoh, A., Ogawa, T., Arakawa, S., Ohbayashi, C. and Kamidono, S. (1996) Two Cases of Small Cell Carcinoma of the Prostate. Scandinavian Journal of Urology and Nephrology, 30, 503-508.
https://doi.org/10.3109/00365599609182334
[25]  Di, Y., Song, J., Song, Z., Wang, Y. and Meng, L. (2024) Prognostic Nomogram to Predict Cancer-Specific Survival with Small-Cell Carcinoma of the Prostate: A Multi-Institutional Study. Frontiers in Oncology, 14, Article 1349888.
https://doi.org/10.3389/fonc.2024.1349888
[26]  Deorah, S., Rao, M.B., Raman, R., Gaitonde, K. and Donovan, J.F. (2011) Survival of Patients with Small Cell Carcinoma of the Prostate during 1973-2003: A Population-Based Study. BJU International, 109, 824-830.
https://doi.org/10.1111/j.1464-410x.2011.10523.x
[27]  Capizzello, A., Peponi, E., Simou, N., Ntaskagiannis, D., Tasiou, I., Kamina, S., et al. (2011) Pure Small Cell Carcinoma of the Prostate: A Case Report and Literature Review. Case Reports in Oncology, 4, 88-95.
https://doi.org/10.1159/000324717
[28]  Rajeswaran, K., Muzio, K., Briones, J., Lim-Fat, M.J., Tseng, C.L., Smoragiewicz, M., Detsky, J. and Emmenegger, U. (2022) Prostate Cancer Brain Metastasis: Review of a Rare Complication with Limited Treatment Options and Poor Prognosis. Journal of Clinical Medicine, 11, 4165.
https://doi.org/10.3390/jcm11144165
[29]  Yildirim, Y., Akcay, Y., Ozyilkan, O. and Celasun, B. (2008) Prostate Small Cell Carcinoma and Skin Metastases: A Rare Entity. Medical Principles and Practice, 17, 250-252.
https://doi.org/10.1159/000117801
[30]  Aggarwal, R.R., Quigley, D.A., Huang, J., Zhang, L., Beer, T.M., Rettig, M.B., et al. (2019) Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Molecular Cancer Research, 17, 1235-1240.
https://doi.org/10.1158/1541-7786.mcr-18-1101
[31]  Aoki, H., Ishidoya, S., Ito, A., Endoh, M., Shimazui, T. and Arai, Y. (2006) Experience of the Treatment with Gemcitabine, Docetaxel, and Carboplatin (GDC) Chemotherapy for Patients with Small-Cell Carcinoma of the Prostate. International Journal of Urology, 13, 1254-1258.
https://doi.org/10.1111/j.1442-2042.2006.01514.x
[32]  Corella, A.N., Cabiliza Ordonio, M.V.A., Coleman, I., Lucas, J.M., Kaipainen, A., Nguyen, H.M., et al. (2020) Identification of Therapeutic Vulnerabilities in Small-Cell Neuroendocrine Prostate Cancer. Clinical Cancer Research, 26, 1667-1677.
https://doi.org/10.1158/1078-0432.ccr-19-0775
[33]  Beltran, H. and Demichelis, F. (2021) Therapy Considerations in Neuroendocrine Prostate Cancer: What Next? Endocrine-Related Cancer, 28, T67-T78.
https://doi.org/10.1530/erc-21-0140
[34]  Koutsilieris, M., Mitsiades, C.S., Bogdanos, J., Dimopoulos, T., Karamanolakis, D., Milathianakis, C., et al. (2004) Combination of Somatostatin Analog, Dexamethasone, and Standard Androgen Ablation Therapy in Stage D3 Prostate Cancer Patients with Bone Metastases. Clinical Cancer Research, 10, 4398-4405.
https://doi.org/10.1158/1078-0432.ccr-04-0077

Full-Text

Contact Us

[email protected]

QQ:3279437679

WhatsApp +8615387084133